Liver transplantation in a patient with hepatitis B, C and D coinfection associated with hepatocellular carcinoma
a management strategy for a rare condition. Case report
Keywords:
Hepatitis B, Hepatitis C, Hepatitis D, Carcinoma, hepatocellular, Liver transplantationAbstract
CONTEXT: Orthotopic liver transplantation (OLT) is the treatment of choice for end-stage liver disease. Cirrhosis due to hepatitis C infection is the leading indication for liver transplantation worldwide. How-ever, patients who are given transplants because of viral liver diseases often present clinical coinfections, including hepatitis B together with hepatitis D. Currently, different strategies exist for patient management before and after liver transplantation, and these are based on different protocols developed by the special-ized transplantation centers. CASE REPORT: We present a rare case of a 58-year-old man with chronic hepatitis B, C and D coinfection. The patient developed cirrhosis and hepatocellular carcinoma. His treatment comprised antiviral therapy for the three viruses and OLT. The patient’s outcome was satisfactory. CONCLUSION: OLT, in association with antiviral therapy using entecavir, which was administered before and after transplantation, was effective for sustained clearance of the hepatitis B and D viruses. A recur-rence of hepatitis C infection after transplantation responded successfully to standard treatment compris-ing peginterferon alfa-2A and ribavirin.
Downloads
References
Crespo G, Mariño Z, Navasa M, Forns X. Viral hepatitis in liver transplantation. Gastroenterology. 2012;142(6):1373-1383.e1.
Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology. 2002;122(4):889-96.
Roche B, Samuel D. Liver transplantation in delta virus infection. Semin Liver Dis. 2012;32(3):245-55.
Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693-9.
Shiroma RK, Chaib E, Amed-Filho AM, et al. Transplante de fígado de acordo com os critérios de Milão: revisão dos últimos 10 anos [Liver transplantation according to Milan criteria an overview of the past ten years]. Revista de Medicina. 2012;91(2):120-4. Available from: file:///C:/ Users/Dell/Downloads/58968-75760-1-PB.pdf. Accessed in 2014 (Dec 3).
Otto G, Schuchmann M, Hoppe-Lotichius M, et al. How to decide about liver transplantation in patients with hepatocellular carcinoma: size and number of lesions or response to TACE? J Hepatol. 2013;59(2):279-84.
Garcia-Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med. 2010;362(9):823-32.
Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Vigilância Epidemiológica. Hepatites virais: o Brasil está atento. 3a ed. Brasília: Ministério da Saúde; 2008. Available from: http://bvsms.saude.gov.br/bvs/publicacoes/hepatites_virais_brasil_ atento_3ed.pdf. Accessed in 2014 (Dec 3).
Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology. 2006;43(5):954-60.
Mathurin P, Thibault V, Kadidja K, et al. Replication status and histological features of patients with triple (B, C, D) and dual (B, C) hepatic infections. J Viral Hepat. 2000;7(1):15-22.
Jardi R, Rodriguez F, Buti M, et al. Role of hepatitis B, C, and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference. Hepatology. 2001;34(2):404-10.
Grabowski J, Wedemeyer H. Hepatitis delta: immunopathogenesis and clinical challenges. Dig Dis. 2010;28(1):133-8.
Heidrich B, Manns MP, Wedemeyer H. Treatment options for hepatitis delta virus infection. Curr Infect Dis Rep. 2013;15(1):31-8.
Mumtaz K, Ahmed US, Memon S, et al. Virological and clinical characteristics of hepatitis delta virus in South Asia. Virol J. 2011;8:312.
Riaz M, Idrees M, Kanwal H, Kabir F. An overview of triple infection with hepatitis B, C and D viruses. Virol J. 2011;8:368.
Lu SN, Chen TM, Lee CM, et al. Molecular epidemiological and clinical aspects of hepatitis D virus in a unique triple hepatitis viruses (B, C, D) endemic community in Taiwan. J Med Virol. 2003;70(1):74-80.
Dantas TO. Aspectos epidemiológicos da infecção pelo vírus da Hepatite C e coinfecções com os vírus B e Delta no Estado do Acre, Amazônia ocidental brasileira [Epidemiological aspects of the hepatitis C virus infection, and its coinfection with the hepatitis B and D virus, in the state of Acre, Western Brazilian Amazon] [Thesis]. Brasília: Universidade de Brasília, Núcleo de Medicina Tropical; 2010. Available from: http://repositorio.unb.br/handle/10482/8157. Accessed in 2014 (Dec 3).
Tsatsralt-Od B, Takahashi M, Nishizawa T, et al. High prevalence of dual or triple infection of hepatitis B, C, and delta viruses among patients with chronic liver disease in Mongolia. J Med Virol. 2005;77(4):491-9.
Zahedi MJ, Darvish Moghaddam S, Alavian SM, Dalili M. Seroprevalence of Hepatitis Viruses B, C, D and HIV Infection Among Hemodialysis Patients in Kerman Province, South-East Iran. Hepat Mon. 2012;12(5):339-43.
Neves SAVM. Estudo soroepidemiológico das hepatites B e Delta na população de doze municípios do estado do Acre, Brasil [Thesis]. Brasília: Universidade de Brasília, Faculdade de Medicina, Programa de Pós-Graduação em Medicina Tropical; 2003. Available from: http://repositorio.unb.br/handle/10482/13197. Accessed in 2014 (Dec 3).
El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365(12): 1118-27.
Oh JK, Shin HR, Lim MK, et al. Multiplicative synergistic risk of hepatocellular carcinoma development among hepatitis B and C co-infected subjects in HBV endemic area: a community-based cohort study. BMC Cancer. 2012;12:452.
Kucirka LM, Farzadegan H, Feld JJ, et al. Prevalence, correlates, and viral dynamics of hepatitis delta among injection drug users. J Infect Dis. 2010;202(6):845-52.
Jiang L, Jiang LS, Cheng NS, Yan LN. Current prophylactic strategies against hepatitis B virus recurrence after liver transplantation. World J Gastroenterol. 2009;15(20):2489-99.
Wesdorp DJ, Knoester M, Braat AE, et al. Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective. J Clin Virol. 2013;58(1):67-73.
Genzini T, Dos Santos RG, Pedrosa C et al. Liver transplantation in bearers of hepatitis B associated or not with delta hepatitis in the age of the new antiviral drugs: is hyperimmune globulin still necessary? Transplant Proc. 2010;42(2):496-7.
Wang P, Tam N, Wang H, et al. Is hepatitis B immunoglobulin necessary in prophylaxis of hepatitis B recurrence after liver transplantation? A meta-analysis. PloS One. 2014;9(8):e104480.
Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol. 2008;49(2):274-87.
Taniguchi M, Shakil AO, Vargas HE, et al. Clinical and virologic outcomes of hepatitis B and C viral coinfection after liver transplantation: effect of viral hepatitis D. Liver Transpl. 2000;6(1):92-6.
Schmidt A, Tzanova I, Köbler AM, Wisser GJ, Kentner R. Orthotopic liver transplantation in a malignant hyperthermia susceptible patient. J Clin Anesth. 2005;17(7):558-61.
